To purchase hard copies of this book, please email:
orders@intechopen.com
Share this page
This book is indexed in
Pharmacology, Toxicology and Pharmaceutical Science
Drug Development - A Case Study Based Insight into Modern Strategies
Edited by Chris Rundfeldt, ISBN 978-953-307-257-9, Hard cover, 654 pages, Publisher: InTech, Chapters published December 07, 2011 under CC BY 3.0 license
DOI: 10.5772/2435
This book represents a case study based overview of many different aspects of drug development, ranging from target identification and characterization to chemical optimization for efficacy and safety, as well as bioproduction of natural products utilizing for example lichen. In the last section, special aspects of the formal drug development process are discussed. Since drug development is a highly complex multidisciplinary process, case studies are an excellent tool to obtain insight in this field. While each chapter gives specific insight and may be read as an independent source of information, the whole book represents a unique collection of different facets giving insight in the complexity of drug development.
- Chapter 1
Discovery and Optimization of Inhibitors of DNA Methyltransferase as Novel Drugs for Cancer Therapy - Chapter 2
Development of Novel Secondary Hormonal Therapies for Castrate-Resistant Prostate Cancer - Chapter 3
Inhibitors of Proteinases as Potential Anti-Cancer Agents - Chapter 4
Histamine Receptors as Potential Therapeutic Targets for Cancer Drug Development - Chapter 5
Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties - Chapter 6
Antimicrobial Peptides: New Frontiers in the Therapy of Infections - Chapter 7
microRNAs as Therapeutic Targets to Combat Diverse Human Diseases - Chapter 8
Potentiation of Available Antibiotics by Targeting Resistance – An Emerging Trend in Tuberculosis Drug Development - Chapter 9
Antitubercular Drugs Development: Recent Advances in Selected Therapeutic Targets and Rational Drug Design - Chapter 10
Insight into the Key Structural Features of Potent Enoyl Acyl Carrier Protein Reductase Inhibitors Based on Computer Aided Molecular Design - Chapter 11
RNA Interference-Based Therapeutics: Harnessing the Powers of Nature - Chapter 12
P2X Receptors as New Therapeutic Targets - Chapter 13
Pregnane X Receptor in Drug Development - Chapter 14
Crosstalk Between the Immune and Central Nervous Systems with Special Reference to Drug Development - Chapter 15
Liquiritigenin Attenuates Alzheimer’s-Like Neuropathology in an Amyloid Protein Precursor Transgenic Mouse Model and the Underlying Mechanisms - Chapter 16
Novel Therapeutic Strategies for Chagas` Disease - Chapter 17
The Gut Microbiota as Target for Innovative Drug Development: Perspectives and a Case Study of Inflammatory Bowel Diseases - Chapter 18
Endophytic Fungi of Tropical Forests: A Promising Source of Bioactive Prototype Molecules for the Treatment of Neglected Diseases - Chapter 19
Bioproduction of Depsidones for Pharmaceutical Purposes - Chapter 20
Multi-Dose Container for Nasal and Ophthalmic Drugs: A Preservative Free Future? - Chapter 21
Microneedle-Assisted Transdermal Delivery of Opioid Antagonists for the Treatment of Alcoholism - Chapter 22
Innovative Proposals for Incentivizing Drug Development - Chapter 23
Drug Experimentation in Healthy Volunteers - Chapter 24
Changes in Research and Development of Medicinal Products since the Paediatric Regulation
